Another $8M for Dyax in Stock Deal

Dyax (NASDAQ: DYAX), a Cambridge, MA-based developer of a drug for an inflammatory disease, has raised $59.6 million in a stock deal. Last month the company raised $51.8 million through the sale of 17 million shares at $3.25 per share, and raised an additional $8 million when underwriter Jefferies & Company exercised its over-allotment option to purchase an additional 2.55 million shares of common stock at $3.25 per share, in a sale that closed today. The funding from the stock offering will go to Dyax’s Kalbitor (ecallantide), a drug for treating acute attacks of an inflammatory disease called hereditary angioedema.

Trending on Xconomy